UroGen Pharma获得美国FDA批准ZUSDURI™作为复发性LG-IR-NMIBC的首个治疗方案UroGen Pharma Receives U.S. FDA Approval for ZUSDURI™ as First Treatment for Recurrent LG-IR-NMIBC

动脉网
13 Jun

UroGen Pharma has received approval from the U.S. Food and Drug Administration (FDA) for ZUSDURI™ (mitomycin) for intravesical use, marking it as the first and only approved treatment for adults with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10